Watch Dan Crenshaw discuss his legislation authorizing trials on psychedelic drug therapy at the Department of Defense
Giving veterans and active duty service members access to psychedelic therapy to treat PTSD has been a top priority for me for years now in Congress. This mission has always been personal. I’ve lost brothers to invisible wounds of PTSD, and I’ve watched others recover when nothing else worked.
That’s why I passed a law authorizing trials on psychedelic therapies like psilocybin and ibogaine through the Department of Defense. Stanford’s study on ibogaine showed an 88% drop in PTSD symptoms, 87% reduction in depression, and 81% decrease in anxiety for veterans with traumatic brain injury. These promising treatments can save lives.
I’m more encouraged about the potential for progress on this issue than I have been in a long time. President Trump has real advocates for this therapy in top positions within his administration, including Health and Human Services Secretary RFK Jr. With the Trump Administration’s openness and strong bipartisan support for this policy, we’re closer than ever to ensuring we fully research the potential clinical benefits of breakthrough therapies so we can get veterans the treatment they need.
